The expiration of patents for blockbuster weight-loss drugs such as Wegovy and Mounjaro in India has led to a significant influx of generic versions into the market, targeting a niche but expanding population willing to pay a premium for rapid weight loss [1]. Consumers like Ameya Nagarajan are paying up to 25,000 rupees ($270) monthly for these drugs, which is 20% higher than the average monthly income of a salaried Indian [1]. Despite the entry of generics, original drugs from Novo Nordisk and Eli Lilly continue to command high levels of trust among physicians and patients, with experts suggesting that the generics may not immediately erode the market share of established brands [1].
Market analysts anticipate that increased competition from generics will gradually drive down prices, ultimately benefiting consumers, although the current cost remains a significant financial burden for many [1]. A Bengaluru-based pharmaceutical analyst noted that while established brands retain reliability, price-sensitive consumers are increasingly opting for generics [1]. The Indian anti-obesity drug market is relatively small compared to global standards but is expected to grow rapidly as awareness and affordability improve [1].
Industry observers are closely monitoring whether generics can gain traction in a market characterized by high out-of-pocket medical spending and limited insurance coverage [1]. Technical indicators suggest that overall sector volume will increase, but manufacturers may face squeezed margins as competition intensifies [1]. No major trading advice was issued, but analysts remain watchful as price levels and consumer preferences evolve in India's pharmaceutical landscape [1].
CONCLUSION
The expiration of patents for Wegovy and Mounjaro has opened the Indian market to generics, increasing competition and potentially lowering prices over time. While established brands retain strong trust, the market is poised for growth as generics gain traction among price-sensitive consumers. Analysts are cautiously optimistic, expecting expanded access but noting that margins may tighten for manufacturers.